Table of Contents > Interactions & Depletions > Aortic acid Print

Aortic acid



Interactions

Aortic acid/Drug Interactions:
  • Antiangiogenic drugsAntiangiogenic drugs: Based on an animal study, aortic extract may inhibit vascularization (23).
  • AnticoagulantsAnticoagulants: Based on human studies, aortic acid may reduce the formation of blood clots (2; 3; 4; 5), and mesoglycan may regulate fibrinolysis (19; 20; 21).
  • Antidiabetic agentsAntidiabetic agents: Based on a clinical trial, mesoglycan may slightly lower serum glucose (27).
  • Antilipemic agentsAntilipemic agents: Based on human studies, aortic acid may lower total cholesterol and VLDL-triglyceride levels while raising HDL cholesterol and lipoprotein lipase activity (2; 3; 22; 11).
  • AntihypertensivesAntihypertensives: Based on a rat study, aortic extract, which contains arginine vasopressin, may produce pressor responses (9).
  • Antineoplastic agentsAntineoplastic agents: Based on animal and in vitro study, aortic extracts may inhibit the growth of tumors (24).
  • Cigarette smokeCigarette smoke: Based on an animal study, cigarette smoke may reduce the activity of aortic acid (25).
  • Fibrinolytic drugsFibrinolytic drugs: Based on human study, mesoglycan may decrease fibrinogen concentration (22) and regulate fibrinolysis (19; 20; 21).
  • Hormonal agentsHormonal agents: Based on an animal study, female sex hormones may affect aortic acid mucopolysaccharides' effect on atherosclerosis (18).
  • ImmunomodulatorsImmunomodulators: Based on an in vitro study, bovine aorta extract may exert significant dose-dependent inhibition of lymphocyte response (26).
  • Thyroid drugsThyroid drugs: Based on an animal study, thyroid drugs may affect aortic acid mucopolysaccharides' effect on atherosclerosis (28).
  • V1-receptor antagonistsV1-receptor antagonists: Based on a rat study, aortic acid may antagonize arginine vasopression V1 antagonists to blunt the hypotensive effect (9).

Aortic acid/Herb/Supplement Interactions:
  • AnticoagulantsAnticoagulants: Based on human studies, aortic acid may reduce the formation of blood clots (2; 3; 4; 5), and mesoglycan may regulate fibrinolysis (19; 20; 21).
  • AntilipemicsAntilipemics:: Based on human studies, aortic acid may lower total cholesterol and VLDL-triglyceride levels while raising HDL cholesterol and lipoprotein lipase activity (2; 3; 22; 11).
  • AntineoplasticsAntineoplastics: Based on animal and in vitro study, aortic extracts may inhibit the growth of tumors (24).
  • CopperCopper: Based on an animal study, copper deficiency may lead to an increase in aortic acid (29).
  • Estrogenic or progestin herbsEstrogenic or progestin herbs: Based on an animal study, female sex hormones may affect aortic acid mucopolysaccharides' effect on atherosclerosis (18).
  • HypoglycemicsHypoglycemics: Based on a clinical trial, mesoglycan may slightly lower serum glucose (27).
  • HypotensivesHypotensives: Based on a rat study, aortic extract may produce pressor responses that are significantly attenuated by pretreatment with a specific arginine vasopressin V1-receptor antagonist (9).
  • ImmunomodulatorsImmunomodulators: Based on an in vitro study, bovine aorta extract may exert significant dose-dependent inhibition of lymphocyte response (26).
  • Thyroid herbsThyroid herbs: Based on an animal study, thyroid drugs may affect aortic acid mucopolysaccharides' effect on atherosclerosis (28).
  • Vitamin CVitamin C: Based on an animal study, administration of vitamin C during copper deficiency may lead to an increase in aortic acid (29).

Aortic acid/Food Interactions:
  • Insufficient available evidence.

Aortic acid/Lab Interactions:
  • Alkaline phosphataseAlkaline phosphatase: Based on a clinical trial, mesoglycan may slightly influence alkaline phosphatase (27).
  • CholesterolCholesterol: Based on a clinical trial, mesoglycan may slightly influence cholesterol (27). However, based on other clinical studies, aortic acid may significantly lower total cholesterol and VLDL-triglyceride levels while raising HDL cholesterol and lipoprotein lipase activity (2; 3; 22; 11).
  • Coagulation panelCoagulation panel: Based on a clinical trial, mesoglycan may slightly influence coagulation time (27). However, in on other clinical studies, mesoglycan had a more pronounced effect on coagulation (2; 3; 4; 5).
  • CreatinineCreatinine: Based on a clinical trial, mesoglycan may slightly influence creatinine (27).
  • FibrinogenFibrinogen: Based on a clinical trial, mesoglycan may slightly influence fibrinogen (27). However, based on other clinical studies, fibrinogen plasma concentration may significantly decrease (22) or regulate fibrinolysis (19; 20; 21).
  • Glutamic oxalocetic transaminase (GOT)Glutamic oxalocetic transaminase (GOT): Based on a clinical trial, mesoglycan may slightly influence glutamic oxalocetic transaminase (27).
  • Glutamic pyruvic transaminaseGPT)Glutamic pyruvic transaminase (GPT): Based on a clinical trial, mesoglycan may slightly influence glutamic pyruvic transaminase (27).
  • Serum glucoseSerum glucose: Based on a clinical trial, mesoglycan may slightly influence serum glucose (27).
  • TriglyceridesTriglycerides: Based on a clinical trial, mesoglycan may slightly influence triglycerides (27). However, based on another clinical study, triglycerides may significantly decrease (22).
  • UreaUrea: Based on a clinical trial, mesoglycan may slightly influence urea (27).

Copyright 2011 Natural Standard (www.naturalstandard.com)


The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.